<DOC>
	<DOCNO>NCT00851552</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth cancer cell block enzymes need cell growth block blood flow cancer . Drugs use chemotherapy , doxorubicin hydrochloride liposome , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer cell growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cell-killing substance . Giving bortezomib together doxorubicin hydrochloride liposome rituximab may kill cancer cell . PURPOSE : This phase II trial study well give bortezomib together doxorubicin hydrochloride liposome rituximab work treat patient diffuse large B-Cell lymphoma relapse responded treatment .</brief_summary>
	<brief_title>Bortezomib , Doxorubicin Hydrochloride Liposome , Rituximab Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed Not Responded Treatment</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine overall objective response rate ( i.e. , complete partial response ) patient relapsed refractory , CD20-positive , diffuse large B-cell lymphoma treat bortezomib , pegylated liposomal doxorubicin hydrochloride , rituximab . Secondary - To assess toxicity/safety profile associate regimen . - To conduct correlative translational research study . OUTLINE : Patients receive bortezomib IV day 1 , 4 , 8 , 11 , pegylated liposomal doxorubicin hydrochloride IV day 11 , rituximab IV day 8 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Tissue blood sample collect periodically correlative study . Samples analyzed expression CD11b/CD18 , CD32 , CD 33 , CD62 , CD64 , CD69 , CD56 flow cytometric analysis neutrophil , NK cell , monocyte ; antibody-dependent cellular complement-mediated cytotoxicity ; genotypic analysis polymorphism PCR . Autologous neoplastic B-cells derive tissue sample use genetic protein profiling . After completion study therapy , patient follow periodically 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis CD20positive diffuse large Bcell lymphoma , include follow morphological variant : Centroblastic Immunoblastic Tcell/histiocyterich Anaplastic Mediastinal ( thymic ) large Bcell lymphoma Intravascular large Bcell lymphoma Relapsed refractory disease Measurable disease , define tumor size 2 cm² Must receive ≥ 1 prior standard chemotherapy regimen No Burkitt precursor Blymphoblastic lymphoma No brain involvement evidence CNS lymphoma PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 70100 % OR ECOG PS 02 Life expectancy ≥ 12 week Absolute neutrophil count ≥ 1,500/μL* Platelet count ≥ 100,000/μL* Creatinine &lt; 2.5 mg/dL OR &gt; 40 mL/min* Hemoglobin &gt; 8.0 g/dL* AST/ALT &lt; 2 time upper limit normal ( ULN ) ( &lt; 3 time ULN liver involvement ) * Alkaline phosphatase &lt; 2 time ULN ( &lt; 3 time ULN liver involvement ) * Total bilirubin &lt; 2 time ULN ( &lt; 3 time ULN liver involvement Gilbert disease ) * NOTE : *Unless attributable nonHodgkin lymphoma LVEF ≥ 50 % MUGA scan ECHO Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month completion therapy No HIV positivity No hepatitis B positivity Peripheral neuropathy &lt; grade 2 defined NCI CTCAE v 3.0 No history uncontrolled orthostatic hypotension None follow cardiac condition : Myocardial infarction within past 6 month New York Heart Association class IIIV congestive heart failure Uncontrolled angina Severe uncontrolled ventricular arrhythmia Clinically significant pericardial disease ECG evidence acute ischemic active conduction system abnormalities No hypersensitivity bortezomib , boron , mannitol No history allergic reaction compound contain boron , mannitol , bortezomib , conventional formulation doxorubicin hydrochloride , component pegylated liposomal doxorubicin hydrochloride No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Poorly control hypertension Diabetes mellitus Serious medical psychiatric condition would interfere adherence completion study No primary malignancy except squamous cell basal cell carcinoma skin , situ carcinoma cervix , superficial bladder carcinoma , previously treat localized prostate cancer normal PSA level diseasefree ≥ 5 year PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered significant toxicity associate prior surgery , radiotherapy , chemotherapy , immunotherapy Prior rituximab monoclonal immunotherapy allow More 4 week since prior investigational drug More 4 week since prior chemotherapy More 4 week since prior major surgery , diagnostic surgery No prior doxorubicin hydrochloride ( equivalent ) anthracycline treatment exceed 400 mg/m² No concurrent corticosteroid , except control transient inflammatory reaction ( i.e. , skin rash hive ) Concurrent nonsteroidal hormone administer nonlymphoma related condition ( e.g. , insulin diabetes ) allow No concurrent radiotherapy No concurrent antitumor chemotherapeutic agent No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
</DOC>